PARIS: Jazz Pharmaceuticals Plc agreed to buy Celator Pharmaceuticals Inc for about US$1.5bil to gain an experimental medicine for a rare blood cancer.
Jazz, based in Dublin, offered US$30.25 per share in cash for Ewing, New Jersey-based Celator, the companies said in a joint statement on Tuesday. Celator's board endorsed the transaction. Investors with 18.4% of Celator's stock, including managers and board members, agreed to tender their shares.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
